Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785393 · ClinicalTrials.gov registry record · Phase 1
DOX as a Potential Treatment for Methamphetamine Dependence
A Phase 1 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02785393 is a Phase 1 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT02785393, a Phase 1 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of the study is to asses the potential interactions between methamphetamine and doxazosin in methamphetamine-dependent volunteers who are not seeking treatment. The study will evaluate the effects of doxazosin on the cardiovascular and subjective effects of methamphetamine in a human laboratory study. The primary objective is to determine the safety of treatment with doxazosin in methamphetamine-dependent volunteers by examining hemodynamic and subjective effects of administration of ascending doses of methamphetamine and a placebo dose during treatment with doxazosin. The secondary objective is to determine effects of treatment with doxazosin, as compared to placebo, on subjective effects produced by administration of methamphetamine or placebo
Interventions
- DRUG Doxazosin
- DRUG Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02785393
The ClinicalTrials.gov registry entry for NCT02785393 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxazosin is the first listed.
NCT02785393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02785393 about?
NCT02785393 is a clinical study titled "DOX as a Potential Treatment for Methamphetamine Dependence". The purpose of the study is to asses the potential interactions between methamphetamine and doxazosin in methamphetamine-dependent volunteers who are not seeking treatment. The study will evaluate the effects of doxazosin on the cardiovascular and subjective effects of methamphetamine in a human lab...
What is the current status of trial NCT02785393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02785393?
The interventions under investigation include: Doxazosin (DRUG), Sugar Pill (DRUG).
Who is sponsoring clinical trial NCT02785393?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.